Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 260

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 260
---
 is based on the share price volatility observed for comparable publicly traded companies over a period similar to the life of the options. The expected option life represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on Canadian government bonds with a remaining term equal to the expected life of the options.

8. Net loss per share

Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:

|                                                                      |   | Year ended December 31, 
                    2024 |   |   |       2023 |   |
|:---------------------------------------------------------------------|:--|------------------------:|:--|:--|-----------:|:--|
| Net loss attributable to shareholders                                | $ |             (11,155,516 | ) | $ | (5,314,765 | ) |
| Weighted average number of common shares outstanding during the year |   |               9,619,184 |   |   |  3,479,494 |   |
| Basic and diluted net loss per share attributable to shareholders    | $ |                   (1.16 | ) | $ |      (1.53 | ) |

The Company's potentially dilutive securities as of December 31, 2024 and 2023, include stock options, warrants, notes payable, convertible promissory notes and preferred shares. The Company excluded the potential ordinary shares outstanding at each period end from the computation of diluted net loss per share attributable to ordinary shareholders for the period ended December 31, 2024 and 2023 because including them would have had an anti-dilutive effect.

9. Income taxes

For the years ended December 31, 2024 and 2023, the total net loss and comprehensive loss is as follows:

|                                          |     | Year ended December 31, 
 2024                    |   |     | 2023       |   |
|:-----------------------------------------|:----|:------------------------|:--|:----|:-----------|:--|
| Loss attributed to US foreign operations |     | (4,968,344              | ) |     | (2,023,786 | ) |
| Loss attributed to Canadian operations   |     | (6,187,172              | ) |     | (3,290,979 | ) |
| Loss before income taxes                 |     | (11,155,516             | ) |     | (5,314,765 | ) |

A reconciliation